EU expands Gilead Trodelvy role in metastatic breast cancer
The European Commission grants marketing authorization for Gilead’s Trodelvy with Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer and expands its role across PD-L1 status.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.